Overall Program Content

This activity will educate clinicians about the use of evidence-based treatments for the effective management of schizophrenia. The activity provides a thorough analysis of currently available oral and injectable medications used in the treatment of schizophrenia. It also examines team-based approaches to the development of patient-centered treatment plans, strategies for overcoming treatment barriers, and the use of evidence-based practices to guide treatment interventions. Finally, there will be 3 optional live/recorded workshops offered for participants who have completed the online modules and would like a case-based opportunity to practice applying the information with the guidance/feedback of course faculty. The workshops will also include ample time for facilitators to address participant questions.

Overall Learning Objectives

Examine currently available oral and long-acting injectable (LAI) antipsychotics for the treatment of schizophrenia.
Identify considerations for the proper administration of intramuscular injections.
Discuss the development and use of recovery plans in the effective management of schizophrenia.
Examine key considerations for overcoming treatment barriers in the treatment of schizophrenia.
Explain the use of evidence-based practices to evaluate medication interventions in schizophrenia.

Activity Format

This continuing education activity consists of 5 self-paced online modules (total 4.25 CE hours) plus an optional live case-based workshop (3 CE hours) facilitated by course faculty. Specific sessions listed at the bottom of the page.
To earn CE credit for each self-paced online module: learners must complete the pre-test (not graded), view the video presentation and PDF handout, complete the post-test (score > 70% within three attempts), and complete the online evaluation.
To earn CE credit for a live workshop: learners must participate in the faculty-guided case exercises (each workshop is 1 hour) and complete the online evaluation at the conclusion of the workshop.
To earn CE credit for a recorded workshop: learners must view the recorded faculty-guided case exercises (each workshop is 1 hour) and complete the online evaluation at the conclusion of the workshop.
Pharmacist learners: CE credit will be uploaded directly to your NABP CPE Monitor profile within a few days of completing an evaluation; contact UT Continuing Pharmacy Education if you experience a problem: UTpharmacyCE@austin.utexas.edu (NOTE: pharmacists must notify UT Continuing Pharmacy Education about CE credit corrections within 60 days of module/workshop completion or credit will be forfeited).
All other learners CE: select "View/Print CE Credit" at top of page to view your updated certificate or completed credit hours as you complete each evaluation.

Scientific Chair
Stephen R. Saklad, PharmD, BCPP Director and Clinical Professor Psychiatric Pharmacy Program The University of Texas at Austin College of Pharmacy UT Health San Antonio
Course Faculty
Leslie Citrome, MD, MPH Clinical Professor Psychiatry and Behavioral Sciences New York Medical College	Amanda J. Simonton, MSN, RN, PMHNP-BC School of Nursing,The University of Texas at Austin Psychiatric-Mental Health Nurse Practitioner CARMAhealth
Cristyn Cordova, MSW, LCSW-S Director of Social Work Austin State Hospital	Dawn I. Velligan, Ph. D. Professor Department of Psychiatry UT Health Science Center at San Antonio
Brendon Hogan, PharmD, BCPP Clinical Pharmacy Manager Mental Health and Pain Central Texas Veterans Health Care System

Faculty Financial Disclosures

Stephen R. Saklad, Pharm.D., BCPP has disclosed the following financial relationships: Employee of The University of Texas at Austin College of Pharmacy. Appointed to the Texas Health and Human Services Commission, San Antonio State Hospital and the UT Health San Antonio Long School of Medicine. Consultant for Alkermes, Intra-Cellular Therapies, Genomind, and Karuna. Speakers bureau for Alkermes, Intra-Cellular Therapies, Otsuka, Neurocrine, and Teva. Speaker for several professional organizations. Treasurer (term ended 2019) for the College of Psychiatric and Neurologic Pharmacists Foundation. Business Development Council for the College of Psychiatric and Neurologic Pharmacists. Expert witness on both defendant and plaintiff sides. No direct stock ownership in pharmaceutical corporation.
Brendon Hogan, PharmD, BCPP has no relevant financial relationships to disclose.
Amanda J. Simonton, MSN, RN, PMHNP-BC has no relevant financial relationships to disclose.
Cristyn Cordova, MSW, LCSW-S has no relevant financial relationships to disclose.
Dawn I. Velligan, Ph. D. has disclosed the following financial relationships: Alkermes (consultant), Otsuka (advisory board, speaker), Janssen (advisory board, consulting); on advisory boards and works as a speaker for talks that are typically disease state with a focus on adherence and recovery
Leslie Citrome, MD, MPH has disclosed the following financial relationships: Performed collaborative research with, or received consulting or speaking fees from: Acadia, Alexza, Alkermes, Allergan, AstraZeneca, Avanir, BioXcel, Boehringer Ingelheim, Bristol-Myers Squibb, Eisai, Eli Lilly, Forum, Genentech, Impel, Indivior, Intra-Cellular Therapies, Janssen, Jazz, Lundbeck, Luye, Meiji, Merck, Medivation, Mylan, Neurocrine, Novartis, Noven, Osmotica, Otsuka, Pfizer, Indivior/Reckitt Benckiser, Reviva, Sage, Shire, Sunovion, Takeda, Teva, Valeant, Vanda

Conflict Resolution

The University of Texas at Austin Continuing Pharmacy Education (UT CPE) requires instructors, planners, and other individuals who are in a position to control the content of this activity to disclose (self/spouse) all relevant financial relationships with commercial interests that are related to the content of this activity. For faculty members who reported relevant financial relationships (Saklad, Velligan, Citrome), an additional peer-review of their activity content was performed by two individuals who have field/topic expertise and no financial disclosures or conflicts of interest. The peer reviews concluded that all presentation/program content that has been developed by faculty members who disclosed relevant financial relationships (named above) is evidence-based, balanced, and free from commercial bias.

Peer Reviews

Tawny Smith, PharmD, BCPP
Associate Professor of Psychiatry
The University of Texas at Austin Dell Medical School

Dr. Smith has no relevant financial relationships to disclose.

Brendon Hogan, PharmD, BCPP

Clinical Pharmacy Manager - Mental Health and Pain

Central Texas Veterans Health Care System

Dr. Hogan has no relevant financial relationships to disclose.

Target Audience

This activity is intended for pharmacists, physicians, psychiatrists, advance practice nurses, physician assistants, psychologists, and social workers seeking an advanced level of knowledge/skills regarding the management of schizophrenia. This program offers CPE, CME, and Social Work credit.

Fee

$0.00

CE Hours

7.25

CE Units

0.725

Activity Type

Knowledge

Requirements for CE Credit

Online modules are accredited for a total of 4.25 CE hours (credit is awarded for each individual module after it is completed, no particular sequence is required). To earn CE credit for each online module, participants must successfully complete the pre-test (not for grade), view module content in its entirety, pass the post-test with a minimum score of 70% (< 3 attempts), and complete the module evaluation.

Live workshops (see schedule listed down below) are accredited for 1.0 CE hour each. To earn CE credit for a live workshop, participants must attend the entire activity, participate in case exercises, and complete the online evaluation following the workshop. Participants are encouraged to complete the online modules before participating in the live workshop.

The University of Texas at Austin College of Pharmacy is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. The ONLINE modules are accredited up to 4.25 CE hours and the LIVE workshops are accredited for a total of 3.0 CE hours.

This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education through the joint providership of The UT Health San Antonio Joe R. & Teresa Lozano Long School of Medicine and The University of Texas at Austin College of Pharmacy. The Long San Antonio School of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The Long School of Medicine designates the online activities for a maximum of 4.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

The Long School of Medicine designates the live workshop activity for a maximum of 3.00 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

The American Academy of Physician Assistants (AAPA), American Academy of Nurse Practitioners (AANP) and the American Nurses Credentialing Center (ANCC) accepts certificates of attendance for educational activities certified for AMA PRA Category 1 Credit™ from organizations accredited by the ACCME.

Healthcare professionals receiving a certificate of attendance should consult with their licensing board for information on applicability and acceptance.

The University of Texas at Austin Hicks School of Social Work, Continuing Education Service has been approved by The University of Texas at Austin Hicks School of Social Work to offer continuing education contact hours to social workers. The University of Texas at Austin Hicks School of Social Work, Continuing Education Service has awarded up to 7.25 contact hour(s) of Continuing Social Work Education.

System Requirements:

Please ensure the computer system you plan to use meets the following minimum requirements:

Operating System: Windows 7 or higher, macOS Sierra (10.12) or higher
Internet Browser: Chrome 30 or higher, Firefox 27 or higher, Internet Explorer 11, Microsoft Edge, Safari 9 or higher
Internet connection: Cable, High-speed DSL, and any other medium that is internet accessible
Peripherals: Computer speakers or headphones
Media Viewing Requirements: Adobe Reader, HTML5

Education Disclaimer:

The author(s) of this continuing education activity have made reasonable efforts to ensure that all information contained herein is accurate in accordance with the latest available scientific evidence at the time of publication. However, because information regarding medications, treatment guidelines, and other healthcare information is subject to constant change, the participant is advised to always confirm practice resources before applying any learned information in practice.Activities produced by UT Continuing Pharmacy Education are intended solely for purposes of supplementing health care professionals’ knowledge. The opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of The University of Texas at Austin College of Pharmacy.

Support/Credits

This activity is supported in-part by an educational grant from Alkermes, Inc.

Evaluating Current and Emerging Treatments in the Effective Management of Schizophrenia

ONLINE MODULE 1: Review of Oral & Injectable Treatments for Schizophrenia

Instructions

First you must complete the pre-test before you may access the course content (pre-test is not for grade).
Once you have submitted the pre-test, review the presentation slides and video presentation (links down below).
After you have viewed the video and slides, take the post-test (you will have 3 attempts to pass the test with a score > 70%).
Once the post-test has been successfully completed, the evaluation will become accessible.
Submit the evaluation to receive CE credit and you are ready to move on to the next module.

Activity Details

Objectives

Discuss currently available oral/injectables medications used for schizophrenia.
Explain the advantages and disadvantages of each oral/injectable schizophrenia treatment.

Speaker(s)/Author(s)

Stephen R. Saklad, PharmD, BCPP, Pharm.D., BCPP
Clinical Associate Professor, UT Austin College of Pharmacy / Director, Psychiatric Pharmacy Program, UT Health Science Center San Antonio , UT Austin College of Pharmacy

Activity Number

0067-9999-20-070-H01-P

Release Date: Apr 1, 2020

Credit Expiration Date: Mar 1, 2023